As a leader in microbiome biotechnology, our team capitalizes on an exclusive Asian microbiome biobank to tackle a myriad of diseases including COVID-19, colorectal cancer, obesity, eczema, and autism.

The gut microbiota interact with our human cells to regulate many physiological processes, such as metabolism and immune response, dysbiosis may lead to Weakened Immunity. By G-NiiB testing and technologies, we aim at modulating human gut microbiome to boost our Immunity.



G-NiiB is a microbiome research based company in Hong Kong. We are back by top-notched clinician scientists and scientific team who pioneers the discovery of the human gut microbiome for different diseases including colorectal cancer, obesity and metabolic diseases, as well as childhood diseases including eczema and autism. We develop precision food, next generation probiotics and precision medicine tailored for people in Asia. G-NiiB is the trademark of GenieBiome Ltd.